Automated next-generation profiling of genomic alterations in human cancers

[1]  Brett J. Kennedy,et al.  Abstract 5671: Alignment of TMB measured on clinical samples: Phase IIB of the Friends of Cancer Research TMB Harmonization Project , 2020 .

[2]  S. Baylin,et al.  Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer , 2020, Nature Cancer.

[3]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[4]  David R. Riley,et al.  Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade , 2019, Clinical Cancer Research.

[5]  Qin Li,et al.  Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy , 2019, Journal of Hematology & Oncology.

[6]  M. Arcila,et al.  Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[7]  Olaf Neumann,et al.  Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis , 2018, International journal of cancer.

[8]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Deleuze,et al.  Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer , 2018, Front. Oncol..

[10]  Olaf Neumann,et al.  Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. , 2018, Translational lung cancer research.

[11]  J. Lunceford,et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.

[12]  P. Hofman,et al.  Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not? , 2018, Translational lung cancer research.

[13]  Rachel Karchin,et al.  A machine learning approach for somatic mutation discovery , 2018, Science Translational Medicine.

[14]  Christopher T. Saunders,et al.  Strelka2: fast and accurate calling of germline and somatic variants , 2018, Nature Methods.

[15]  Isabelle Salmon,et al.  Methods of measurement for tumor mutational burden in tumor tissue. , 2018, Translational lung cancer research.

[16]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[17]  Steven J. M. Jones,et al.  Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.

[18]  Li Ding,et al.  Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.

[19]  Mounir A. Ajam.  Gaps and Opportunities , 2018 .

[20]  A. Vadas.  Immuno-Oncology Is Making Pharma Step Up Its Diagnostics Game BY ALEX VADAS , 2018 .

[21]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[22]  Woo Yong Lee,et al.  Prevalence and detection of low-allele-fraction variants in clinical cancer samples , 2017, Nature Communications.

[23]  Russell Bonneville,et al.  Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.

[24]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[25]  D J Mooney,et al.  Tough adhesives for diverse wet surfaces , 2017, Science.

[26]  R. Pe Benito,et al.  Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities , 2017, Clinical lung cancer.

[27]  Jay Shendure,et al.  Classification and characterization of microsatellite instability across 18 cancer types , 2016, Nature Medicine.

[28]  Nikhil Wagle,et al.  The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine , 2016, Genome Medicine.

[29]  A. McGuire,et al.  Barriers to clinical adoption of next generation sequencing: Perspectives of a policy Delphi panel , 2016, Applied & translational genomics.

[30]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[31]  L. Clipson,et al.  Improved Detection of Microsatellite Instability in Early Colorectal Lesions , 2015, PloS one.

[32]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[33]  Theresa Zhang,et al.  Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.

[34]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[35]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[36]  Adam Kiezun,et al.  Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine , 2013, Nature Medicine.

[37]  Dennis C. Friedrich,et al.  Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .

[38]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[39]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[40]  G. Parmigiani,et al.  Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.

[41]  Xuhua Xia,et al.  Position Weight Matrix, Gibbs Sampler, and the Associated Significance Tests in Motif Characterization and Prediction , 2012, Scientifica.

[42]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[43]  Levi A Garraway,et al.  Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.

[44]  Nikhil Wagle,et al.  High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.

[45]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[46]  C. Cole,et al.  COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.

[47]  M. Warmuth,et al.  Targeted Cancer Therapies in the Twenty‐First Century: Lessons From Imatinib , 2010, Clinical pharmacology and therapeutics.

[48]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  A. Duval,et al.  Quasimonomorphic Mononucleotide Repeats for High-Level Microsatellite Instability Analysis , 2004, Disease markers.

[50]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[51]  K. Sirotkin,et al.  dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. , 1999, Genome research.

[52]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.